0.00Open33.20Pre Close0 Volume3 Open Interest220.00Strike Price0.00Turnover45.59%IV0.08%PremiumDec 20, 2024Expiry Date33.01Intrinsic Value100Multiplier18DDays to Expiry0.19Extrinsic Value100Contract SizeAmericanOptions Type0.9269Delta0.0054Gamma7.37Leverage Ratio-0.1214Theta0.0987Rho6.83Eff Leverage0.0780Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet